HONG KONG, Apr 28, 2026 – (ACN Newswire) – CanSino Biologics Inc. (688185.SH/06185.HK) released its first-quarter 2026 results, reflecting a positive operational momentum. Revenue for the quarter totaled RMB 190 million, representing a 38.73% year-over-year increase.The performance highlights the company’s strong operational resilience, driven by accelerating sales of core products and ongoing cost-efficiency measures…
Read More
